April 30th 2025
A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.
April 22nd 2025
A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.
April 21st 2025
The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies.
April 15th 2025
Access USA converges in Philadelphia to explore new—and needed—solutions to boost patient outcomes.
A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.
Pharma's Journey with Patient Family Advisory Councils
Including patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.
Does Patient Priorities Care Result in Better Outcomes for Patients?
A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.
Breaking the Chains of Opioid Addiction: The Promise of Long-Acting Injectables
As providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.
Cell and Gene Therapy Outlook: Q&A with Fran Gregory, VP of Emerging Therapies, Cardinal Health
A discussion of where cell and gene therapies are currently doing, what's on the horizon, personalization, and much more.
The Evolving Role of PBMs: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.
The Impact of Eli Lilly's New DTC Platform on Rx Drug Sales and Patient Access: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.
P360 Builds Out New Artificial Intelligence-Powered Platform
EdenHelp is expected to provide HCPs and patients with real-time access to Rx drug and medical device information.
ixlayer Becomes Member of American Heart Association Center for Health Technology & Innovation Consortium
The group—known as the Innovators' Network—is meant to serve as a link between entrepreneurs, providers, researchers, and payers while they strive to combat cardiovascular disease.
A Closer Look at PBM Spread Pricing
While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.
Diversity Trends in Health Professions Programs
Study examines the parallels between doctorate students and the US population.
Strategic Insight and Forecasting: From Pipeline to Pharmacy
How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.
How Healthcare Economics Outcomes Evidence Can Pave the Way for Digital Therapeutics
In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.
Trade & Channel Strategies 2023: IRA—All the Things Beyond Price Negotiations That Will Impact Your Business
Breakout session summarizes key areas that will affect all aspects of the industry.
Trade & Channel Strategies 2023: An Interview with Bayer's Spencer Miller
Bayer executive talks Enable Holistic Hub and Provider Services panel.
Trade & Channel Strategies 2023: Enabling Holistic Hub and Provider Services
Session discusses ways to integrate digital pharmacies and hubs.
Trade & Channel Strategies 2023: An Interview with Cheryl Allen of Curatio Scientia
Founding Partner of Curatio Scientia speaks on her upcoming panel at Trade & Channel Strategies 2023.
Trade & Channel Strategies 2023: An Interview with Paul Chen of Lexicon Pharmaceuticals
Lexicon Pharmaceuticals exec discusses upcoming Enable Holistic Hub and Provider Services panel.
Trade & Channel Strategies 2023: Aligning Patient Access
Panel uncovers ways to handle the increasing complexities and risks surrounding commercialization.
Is Trust the Secret Ingredient for Digital Product Success?
To rebuild trust, companies should utilize a customer-centric approach, focusing on transparent and neutral content incorporating medical expertise and regularly seeking HCP feedback.
Continued Affordability Challenges in the Offing
Will result from Medicare reforms, despite increased drug uptake.
Transforming the Patient Hub into a Hub of Patient Centricity
Methods that pharma companies can use to make the hub more personalized and experiential.
Navigating the Biosimilars Marketplace
How to provide effective brand engagement in this rocky yet emerging landscape.
An Outlook on Data-Powered Patient Support
Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.
The Importance of the Medical Affairs Function in Pharmaceutical Companies
Study emphasizes role in bridging research and development and commercial/marketing functions.
How Digital Twins Drive Sustainability in Clinical Supply Planning
Digital twins allow the industry to integrate sustainable practices and supply chain efficiency solutions while ensuring patient safety.
Major PBM to Offer Cost-Based Pricing Option for Prescription Medications
ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.
Project Highlights Benefits of Statistical Methodology Research for Patients, Pharma
New initiative highlights importance of a collaborative approach that allows patients to share their insights and contribute value to studies.
Nordic Capital Purchases Majority Share in IntegriChain
Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.
Access Insights 2023: The Pharmacy of the Future
Conference session discusses the drivers, practical considerations, success factors, and landscape for next-generation pharmacy innovation.
Access Insights 2023: Fight for the Dollar
Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.